DeepMed Research

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs

Not Applicable

Recruiting

Conditions: Cancer

Interventions: Procedure: Blood sample

First Posted Date: 2019-06-13

Last Posted Date: 2024-08-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1240

Registration Number: NCT03984318

Locations: 🇫🇷
Gustave Roussy, Chevilly-Larue, France
🇫🇷
Hôpital Paul Brousse, Villejuif, France
🇫🇷
Hôpital Bicêtre, Le Kremlin-Bicêtre, France

and more 1 locations

Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults

Phase 3

Recruiting

Conditions: Mucositis Oral

Interventions: Other: Placebo
Device: Low-Level Laser Therapy

First Posted Date: 2019-06-12

Last Posted Date: 2025-05-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 315

Registration Number: NCT03983369

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 2 locations

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Phase 2

Withdrawn

Conditions: Triple Negative Breast Cancer
Prostate Adenocarcinoma
Esophageal Adenocarcinoma
Metastatic Colorectal Cancer
Stomach Adenocarcinoma

Interventions: Drug: Tremelimumab
Drug: Durvalumab

First Posted Date: 2019-06-11

Last Posted Date: 2023-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Registration Number: NCT03982173

Video-Based Cognitive Behavioral Therapy for Insomnia in Adults Cancer Patients and Survivors

Not Applicable

Completed

Conditions: Insomnia

Interventions: Other: Questionnaires

First Posted Date: 2019-06-11

Last Posted Date: 2019-06-11

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 177

Registration Number: NCT03981666

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

Phase 1

Withdrawn

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: FOLFOX regimen
Drug: Nivolumab
Drug: GLA-SE
Drug: Ipilimumab

First Posted Date: 2019-06-11

Last Posted Date: 2020-02-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Registration Number: NCT03982121

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Phase 3

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Acetylsalicylic acid
Drug: Atorvastatin

First Posted Date: 2019-01-28

Last Posted Date: 2024-11-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1210

Registration Number: NCT03819101

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Bellinzona Istituto Oncologico, Bellinzona, Switzerland
🇨🇭
Kantonsspital Baselland, Bruderholz, Switzerland

and more 17 locations

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Phase 2

Active, not recruiting

Conditions: Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

Interventions: Drug: Nivolumab cohort 1
Drug: Nivolumab cohort 2

First Posted Date: 2018-10-11

Last Posted Date: 2024-11-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 45

Registration Number: NCT03703050

Locations: 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷
CHU Mondor, Créteil, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 10 locations

Study of a Simplified Geriatric Evaluation Performed by Oncologists Prior to Cancer Treatment by Radiotherapy or Chemotherapy in Subjects Aged 70 Years or Older With Inoperable Squamous Cell Cancer of the Head and Neck

Conditions: Inoperable Squamous Cell Cancer of the Head and Neck

Interventions: Other: Geriatric Screening Test G8
Other: Geriatric fragility test GERICO

First Posted Date: 2018-08-03

Last Posted Date: 2018-08-03

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT03614936

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer

Not Applicable

Conditions: Colorectal Cancer

Interventions: Procedure: Sampling

First Posted Date: 2018-08-03

Last Posted Date: 2018-08-03

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 50

Registration Number: NCT03613194

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab

Phase 2

Active, not recruiting

Conditions: Locally Advanced Cervical Cancer

Interventions: Radiation: Radiotherapy
Drug: Atezolizumab
Drug: Cisplatin

First Posted Date: 2018-08-02

Last Posted Date: 2024-12-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 189

Registration Number: NCT03612791

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy